Methyldopa tablet overdosage: Difference between revisions
Created page with "__NOTOC__ {{Methyldopa}} {{CMG}}; {{AE}} {{AK}} <ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = METHYLDOPA TABLET [CARDINAL HEALTH] | url = h..." |
No edit summary |
||
| Line 3: | Line 3: | ||
{{CMG}}; {{AE}} {{AK}} | {{CMG}}; {{AE}} {{AK}} | ||
==OVERDOSAGE== | |||
Acute overdosage may produce acute [[hypotension ]]with other responses attributable to brain and gastrointestinal malfunction (excessive [[sedation]], weakness, [[bradycardia]], [[dizziness]], light-headedness, [[constipation]], [[distention]], [[flatus]], [[diarrhea]], [[nausea]], [[vomiting]]). | |||
In the event of overdosage, symptomatic and supportive measures should be employed. When ingestion is recent, gastric lavage or [[emesis ]]may reduce absorption. When ingestion has been earlier, infusions may be helpful to promote urinary excretion. Otherwise, management includes special attention to cardiac rate and output, blood volume, electrolyte balance, [[paralytic ileus]], urinary function and cerebral activity. | |||
Sympathomimetic drugs [e.g., [[levarterenol]], [[epinephrine]], ARAMINE®1 ([[Metaraminol ]]Bitartrate)] may be indicated. Methyldopa is [[dialyzable]]. | |||
The oral LD50 of methyldopa is greater than 1.5 g/kg in both the mouse and the rat. | |||
< | <sup>1</sup> | ||
ARAMINE® is a registered trademark of Merck.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = METHYLDOPA TABLET [CARDINAL HEALTH] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d87d63fd-48f7-4130-af03-5e263c338fe4 | publisher = | date = | accessdate = 10 March 2014 }}</ref> | |||
==References== | ==References== | ||
Revision as of 16:04, 10 March 2014
| Methyldopa |
|---|
| Methyldopa tablet® FDA Package Insert |
| Indications and Usage |
| Dosage and Administration |
| Contraindications |
| Warnings |
| Precautions |
| Adverse Reactions |
| Drug Interactions |
| Use in Specific Populations |
| Overdosage |
| Description |
| Clinical Pharmacology |
| Nonclinical Toxicology |
| How Supplied/Storage and Handling |
| Labels and Packages |
| Methyldopa injection® FDA Package Insert |
| Indications and Usage |
| Dosage and Administration |
| Contraindications |
| Warnings |
| Precautions |
| Adverse Reactions |
| Drug Interactions |
| Use in Specific Populations |
| Overdosage |
| Description |
| Clinical Pharmacology |
| Nonclinical Toxicology |
| How Supplied/Storage and Handling |
| Labels and Packages |
| Clinical Trials on Methyldopa |
| ClinicalTrials.gov |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Abdurahman Khalil, M.D. [2]
OVERDOSAGE
Acute overdosage may produce acute hypotension with other responses attributable to brain and gastrointestinal malfunction (excessive sedation, weakness, bradycardia, dizziness, light-headedness, constipation, distention, flatus, diarrhea, nausea, vomiting).
In the event of overdosage, symptomatic and supportive measures should be employed. When ingestion is recent, gastric lavage or emesis may reduce absorption. When ingestion has been earlier, infusions may be helpful to promote urinary excretion. Otherwise, management includes special attention to cardiac rate and output, blood volume, electrolyte balance, paralytic ileus, urinary function and cerebral activity.
Sympathomimetic drugs [e.g., levarterenol, epinephrine, ARAMINE®1 (Metaraminol Bitartrate)] may be indicated. Methyldopa is dialyzable.
The oral LD50 of methyldopa is greater than 1.5 g/kg in both the mouse and the rat.
1
ARAMINE® is a registered trademark of Merck.[1]
References
- ↑ "METHYLDOPA TABLET [CARDINAL HEALTH]". Retrieved 10 March 2014.